1
|
Madjene LC, Danelli L, Dahdah A, Vibhushan S, Bex-Coudrat J, Pacreau E, Vaugier C, Claver J, Rolas L, Pons M, Madera-Salcedo IK, Beghdadi W, El Ghoneimi A, Benhamou M, Launay P, Abrink M, Pejler G, Moura IC, Charles N, Daugas E, Perianin A, Blank U. Mast cell chymase protects against acute ischemic kidney injury by limiting neutrophil hyperactivation and recruitment. Kidney Int 2019; 97:516-527. [PMID: 31866111 DOI: 10.1016/j.kint.2019.08.037] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2018] [Revised: 08/20/2019] [Accepted: 08/29/2019] [Indexed: 12/22/2022]
Abstract
Here we investigated the role of murine mast cell protease 4 (MCPT4), the functional counterpart of human mast cell chymase, in an experimental model of renal ischemia reperfusion injury, a major cause of acute kidney injury. MCPT4-deficient mice had worsened kidney function compared to wildtype mice. MCPT4 absence exacerbated pathologic neutrophil infiltration in the kidney and increased kidney myeloperoxidase expression, cell death and necrosis. In kidneys with ischemia reperfusion injury, when compared to wildtype mice, MCPT4-deficient mice showed increased surface expression of adhesion molecules necessary for leukocyte extravasation including neutrophil CD162 and endothelial cell CD54. In vitro, human chymase mediated the cleavage of neutrophil expressed CD162 and also CD54, P- and E-Selectin expressed on human glomerular endothelial cells. MCPT4 also dampened systemic neutrophil activation after renal ischemia reperfusion injury as neutrophils expressed more CD11b integrin and produced more reactive oxygen species in MCPT4-deficient mice. Accordingly, after renal injury, neutrophil migration to an inflammatory site distal from the kidney was increased in MCPT4-deficient versus wildtype mice. Thus, contrary to the described overall aggravating role of mast cells, one granule-released mediator, the MCPT4 chymase, exhibits a potent anti-inflammatory function in renal ischemia reperfusion injury by controlling neutrophil extravasation and activation thereby limiting associated damage.
Collapse
Affiliation(s)
- Lydia Celia Madjene
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Luca Danelli
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Albert Dahdah
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Shamila Vibhushan
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Julie Bex-Coudrat
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Emeline Pacreau
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Celine Vaugier
- INSERM UMR 1163, Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutic Implications, Paris, France; Imagine Institute, Paris Descartes-Sorbonne Paris Cité University, Laboratory of Excellence GR-Ex, Paris, France; CNRS ERL 8254, Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutic Implications, Paris, France
| | - Julien Claver
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Loïc Rolas
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Maguelonne Pons
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Iris Karina Madera-Salcedo
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Walid Beghdadi
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Alaa El Ghoneimi
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France; Department of Pediatric Surgery and Urology, Hopital Robert Debré, APHP, Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Marc Benhamou
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Pierre Launay
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Magnus Abrink
- Immunology Section, Department of Biomedical Sciences and Veterinary Public Health, Swedish University of Agricultural Sciences, VHC, Uppsala, Sweden
| | - Gunnar Pejler
- Department of Anatomy, Physiology and Biochemistry, Swedish University of Agricultural Sciences, Uppsala, Sweden; Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden
| | - Ivan Cruz Moura
- INSERM UMR 1163, Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutic Implications, Paris, France; Imagine Institute, Paris Descartes-Sorbonne Paris Cité University, Laboratory of Excellence GR-Ex, Paris, France; CNRS ERL 8254, Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutic Implications, Paris, France
| | - Nicolas Charles
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Eric Daugas
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France; Service de Néphrologie, Hôpital Universitaire Bichat-Claude Bernard, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Axel Perianin
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France
| | - Ulrich Blank
- Center of Research on Inflammation, Inserm UMRS-1149, Paris, France; Center of Research on Inflammation, CNRS ERL 8252, Paris, France; Center of Research on Inflammation, Université Paris Diderot, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX, Paris, France.
| |
Collapse
|
2
|
Flores C, Fouquet G, Moura IC, Maciel TT, Hermine O. Lessons to Learn From Low-Dose Cyclosporin-A: A New Approach for Unexpected Clinical Applications. Front Immunol 2019; 10:588. [PMID: 30984176 PMCID: PMC6447662 DOI: 10.3389/fimmu.2019.00588] [Citation(s) in RCA: 45] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2018] [Accepted: 03/05/2019] [Indexed: 01/09/2023] Open
Abstract
Cyclosporin-A has been known and used for a long time, since its "fast track" approval in the early 80's. This molecule has rapidly demonstrated unexpected immunosuppressive properties, transforming the history of organ transplantation. Cyclosporin's key effect relies on modulation on T-lymphocyte activity, which explains its role in the prevention of graft rejection. However, whether cyclosporin-A exerts other effects on immune system remains to be determined. Until recently, cyclosporin-A was mainly used at a high-dose, but given the drug toxicity and despite the fear of losing its immunosuppressive effects, there is nowadays a tendency to decrease its dose. The literature has been reporting data revealing a paradoxical effect of low dosage of cyclosporin-A. These low-doses appear to have immunomodulatory properties, with different effects from high-doses on CD8+ T lymphocyte activation, auto-immune diseases, graft-vs.-host disease and cancer. The aim of this review is to discuss the role of cyclosporin-A, not only as a consecrated immunosuppressive agent, but also as an immunomodulatory drug when administrated at low-dose. The use of low-dose cyclosporin-A may become a new therapeutic strategy, particularly to treat cancer.
Collapse
Affiliation(s)
- Camila Flores
- INSERM UMR1163 and CNRS URL 8254, Imagine Institute, Paris, France.,Paris Descartes University-Sorbonne Paris Cité, Paris, France
| | - Guillemette Fouquet
- INSERM UMR1163 and CNRS URL 8254, Imagine Institute, Paris, France.,Paris Descartes University-Sorbonne Paris Cité, Paris, France
| | - Ivan Cruz Moura
- INSERM UMR1163 and CNRS URL 8254, Imagine Institute, Paris, France.,Paris Descartes University-Sorbonne Paris Cité, Paris, France
| | - Thiago Trovati Maciel
- INSERM UMR1163 and CNRS URL 8254, Imagine Institute, Paris, France.,Paris Descartes University-Sorbonne Paris Cité, Paris, France
| | - Olivier Hermine
- INSERM UMR1163 and CNRS URL 8254, Imagine Institute, Paris, France.,Paris Descartes University-Sorbonne Paris Cité, Paris, France.,Department of Hematology, Necker Children's Hospital, APHP, Paris, France
| |
Collapse
|
3
|
Babdor J, Fricot A, Dussiot M, Hebert L, Dubreuil P, Moura IC, Maciel TT, Hermine O. Abstract 4868: Tyrosine kinase-dependent modulation of tumor infiltrating immune cells in melanoma. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-4868] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Melanoma causes the greatest morbidity and mortality of all skin cancers and often harbors amplifications or activating mutations in KIT, a type III transmembrane receptor tyrosine kinase (RTK) involved in cancer cell growth, migration, invasion and metastasis. At present, no treatment that provide either sufficient response rates or a significant prolongation of overall survival are available for melanoma. In the last decade, several inhibitors of RTK (RTKi) have been developed for the treatment of cancer, however, a number of short-comings was observed. Therefore, novel TK inhibitors with improved selectivity were developed for the treatment of diseases associated with KIT activation. Masitinib (AB1010), a RTKi capable of blocking selectively KIT, is one such new drug. Using B16 melanoma subcutaneous graft on C57Bl6 mice, we demonstrate that Masitinib is able to limit tumor growth in vivo and increase mice survival. This anti-tumoral effect was not observed for other RTKi targeting KIT. Suprisingly, Masitinib has no effect on melanoma proliferation in vitro, suggesting instead that modulation on tumor environment takes place. Indeed, mast cells that accumulate in the tumors secrete several biologically active factors involved in the modulation of tumor growth. In vivo, Masitinib treatment completely abrogates mast cell maturation and migration resulting in decreased tumor invasion and down-regulation of several angiogenic factors. Using a mouse line deficient for mast cells (Wsh/Wsh), we confirmed that Masitinib effect is in part dependent of its inhibition on mast cell migration and maturation. Indeed, additional effect occurs on macrophage polarization leaning from “tolerogenic” toward “anti-tumoral” phenotype. Furthermore, in vivo macrophage depletion favored tumor promotion and reverses Masitinib effect on tumor growth. The results provided by this study suggest that Masitinib may be a useful therapy on melanoma by its dual role on tumor environment. It can block mast cell maturation and infiltration in the tumor site, avoiding the angiogenic effects of mast cells. It can revert tumor tolerent macrophage status leading to an increased inflammatory activity within the tumor microenvironment.
These effects are not observed only on melanoma, but also on other types of cancer, suggesting the cellular mechanisms triggered by Masitinib occur in various tumoral process. For instance, a phase III clinical trial with Masitinib as GIST treatment is currently ongoing.
Citation Format: Joël Babdor, Aurélie Fricot, Michaël Dussiot, Lucile Hebert, Patrice Dubreuil, Ivan Cruz Moura, Thiago Trovati Maciel, Olivier Hermine. Tyrosine kinase-dependent modulation of tumor infiltrating immune cells in melanoma. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4868.
Collapse
Affiliation(s)
- Joël Babdor
- 1Laboratory of Molecular Mechanisms of Hematologic Disorders and Therapeutic Implications. INSERM U1163 - IMAGINE Institut. Paris Descartes University - Sorbonne-Paris-Cité University, Paris, France
| | - Aurélie Fricot
- 1Laboratory of Molecular Mechanisms of Hematologic Disorders and Therapeutic Implications. INSERM U1163 - IMAGINE Institut. Paris Descartes University - Sorbonne-Paris-Cité University, Paris, France
| | - Michaël Dussiot
- 1Laboratory of Molecular Mechanisms of Hematologic Disorders and Therapeutic Implications. INSERM U1163 - IMAGINE Institut. Paris Descartes University - Sorbonne-Paris-Cité University, Paris, France
| | - Lucile Hebert
- 1Laboratory of Molecular Mechanisms of Hematologic Disorders and Therapeutic Implications. INSERM U1163 - IMAGINE Institut. Paris Descartes University - Sorbonne-Paris-Cité University, Paris, France
| | - Patrice Dubreuil
- 2INSERM CRCM - Centre de Recherche en Cancérologie de Marseille, U1068 INSERM, Institut Paoli-Calmettes, CNRS, Université Aix Marseille, Paris, France
| | - Ivan Cruz Moura
- 1Laboratory of Molecular Mechanisms of Hematologic Disorders and Therapeutic Implications. INSERM U1163 - IMAGINE Institut. Paris Descartes University - Sorbonne-Paris-Cité University, Paris, France
| | - Thiago Trovati Maciel
- 1Laboratory of Molecular Mechanisms of Hematologic Disorders and Therapeutic Implications. INSERM U1163 - IMAGINE Institut. Paris Descartes University - Sorbonne-Paris-Cité University, Paris, France
| | - Olivier Hermine
- 1Laboratory of Molecular Mechanisms of Hematologic Disorders and Therapeutic Implications. INSERM U1163 - IMAGINE Institut. Paris Descartes University - Sorbonne-Paris-Cité University, Paris, France
| |
Collapse
|
4
|
Arlet JB, Ribeil JA, Guillem F, Negre O, Hazoume A, Marcion G, Beuzard Y, Dussiot M, Moura IC, Demarest S, de Beauchêne IC, Belaid-Choucair Z, Sevin M, Maciel TT, Auclair C, Leboulch P, Chretien S, Tchertanov L, Baudin-Creuza V, Seigneuric R, Fontenay M, Garrido C, Hermine O, Courtois G. HSP70 sequestration by free α-globin promotes ineffective erythropoiesis in β-thalassaemia. Nature 2014; 514:242-6. [PMID: 25156257 DOI: 10.1038/nature13614] [Citation(s) in RCA: 104] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2013] [Accepted: 06/25/2014] [Indexed: 12/28/2022]
Abstract
β-Thalassaemia major (β-TM) is an inherited haemoglobinopathy caused by a quantitative defect in the synthesis of β-globin chains of haemoglobin, leading to the accumulation of free α-globin chains that form toxic aggregates. Despite extensive knowledge of the molecular defects causing β-TM, little is known of the mechanisms responsible for the ineffective erythropoiesis observed in the condition, which is characterized by accelerated erythroid differentiation, maturation arrest and apoptosis at the polychromatophilic stage. We have previously demonstrated that normal human erythroid maturation requires a transient activation of caspase-3 at the later stages of maturation. Although erythroid transcription factor GATA-1, the master transcriptional factor of erythropoiesis, is a caspase-3 target, it is not cleaved during erythroid differentiation. We have shown that, in human erythroblasts, the chaperone heat shock protein70 (HSP70) is constitutively expressed and, at later stages of maturation, translocates into the nucleus and protects GATA-1 from caspase-3 cleavage. The primary role of this ubiquitous chaperone is to participate in the refolding of proteins denatured by cytoplasmic stress, thus preventing their aggregation. Here we show in vitro that during the maturation of human β-TM erythroblasts, HSP70 interacts directly with free α-globin chains. As a consequence, HSP70 is sequestrated in the cytoplasm and GATA-1 is no longer protected, resulting in end-stage maturation arrest and apoptosis. Transduction of a nuclear-targeted HSP70 mutant or a caspase-3-uncleavable GATA-1 mutant restores terminal maturation of β-TM erythroblasts, which may provide a rationale for new targeted therapies of β-TM.
Collapse
Affiliation(s)
- Jean-Benoît Arlet
- 1] Laboratoire INSERM, unité mixte de recherche 1163, centre national de la recherche scientifique (CNRS) équipe de recherche labellisée 8254, 24 Boulevard de Montparnasse, 75015 Paris, France [2] Service de Médecine Interne, Faculté de médecine Paris Descartes, Sorbonne Paris-Cité et Assistance publique - Hôpitaux de Paris, Hôpital Européen Georges Pompidou, 15 rue Leblanc 75908 Paris, France [3] Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, Assistance publique - Hôpitaux de Paris, Hôpital Necker, 24 Boulevard de Montparnasse, 75015 Paris, France [4] Laboratory of Excellence GR-Ex, 75015 Paris, France [5]
| | - Jean-Antoine Ribeil
- 1] Laboratoire INSERM, unité mixte de recherche 1163, centre national de la recherche scientifique (CNRS) équipe de recherche labellisée 8254, 24 Boulevard de Montparnasse, 75015 Paris, France [2] Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, Assistance publique - Hôpitaux de Paris, Hôpital Necker, 24 Boulevard de Montparnasse, 75015 Paris, France [3] Laboratory of Excellence GR-Ex, 75015 Paris, France [4] Département de Biothérapie, Faculté de médecine Paris Descartes, Sorbonne Paris-Cité et Assistance publique - Hôpitaux de Paris, Hôpital Necker, 149 rue de Sèvres 75015 Paris, France [5]
| | - Flavia Guillem
- 1] Laboratoire INSERM, unité mixte de recherche 1163, centre national de la recherche scientifique (CNRS) équipe de recherche labellisée 8254, 24 Boulevard de Montparnasse, 75015 Paris, France [2] Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, Assistance publique - Hôpitaux de Paris, Hôpital Necker, 24 Boulevard de Montparnasse, 75015 Paris, France [3] Laboratory of Excellence GR-Ex, 75015 Paris, France
| | - Olivier Negre
- Commissariat à l'énergie atomique (CEA), Institute of Emerging Diseases and Innovative Therapies (iMETI), 18 Route du Panorama, 92260 Fontenay-aux-Roses, France
| | - Adonis Hazoume
- 1] INSERM, unité mixte de recherche 866, Equipe labellisée Ligue contre le Cancer and Association pour la Recherche contre le Cancer, and Laboratoire d'Excellence Lipoprotéines et santé (LipSTIC), 21033 Dijon, France [2] University of Burgundy, Faculty of Medicine and Pharmacy, 7 boulevard Jeanne d'Arc, 21033 Dijon, France
| | - Guillaume Marcion
- 1] INSERM, unité mixte de recherche 866, Equipe labellisée Ligue contre le Cancer and Association pour la Recherche contre le Cancer, and Laboratoire d'Excellence Lipoprotéines et santé (LipSTIC), 21033 Dijon, France [2] University of Burgundy, Faculty of Medicine and Pharmacy, 7 boulevard Jeanne d'Arc, 21033 Dijon, France
| | - Yves Beuzard
- Commissariat à l'énergie atomique (CEA), Institute of Emerging Diseases and Innovative Therapies (iMETI), 18 Route du Panorama, 92260 Fontenay-aux-Roses, France
| | - Michaël Dussiot
- 1] Laboratoire INSERM, unité mixte de recherche 1163, centre national de la recherche scientifique (CNRS) équipe de recherche labellisée 8254, 24 Boulevard de Montparnasse, 75015 Paris, France [2] Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, Assistance publique - Hôpitaux de Paris, Hôpital Necker, 24 Boulevard de Montparnasse, 75015 Paris, France [3] Laboratory of Excellence GR-Ex, 75015 Paris, France [4] INSERM, unité mixte de recherche 699, Hôpital Bichat, 46 rue Henri Huchard, 75018 Paris, France
| | - Ivan Cruz Moura
- 1] Laboratoire INSERM, unité mixte de recherche 1163, centre national de la recherche scientifique (CNRS) équipe de recherche labellisée 8254, 24 Boulevard de Montparnasse, 75015 Paris, France [2] Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, Assistance publique - Hôpitaux de Paris, Hôpital Necker, 24 Boulevard de Montparnasse, 75015 Paris, France [3] Laboratory of Excellence GR-Ex, 75015 Paris, France [4] INSERM, unité mixte de recherche 699, Hôpital Bichat, 46 rue Henri Huchard, 75018 Paris, France [5] Faculté de médecine and Université Denis Diderot Paris VII, 5 Rue Thomas Mann, 75013 Paris, France
| | - Samuel Demarest
- Centre national de la recherche scientifique (CNRS), unité mixte de recherche 8113, Ecole Normale Supérieure de Cachan, 61 avenue du président Wilson, 94230 Cachan, France
| | - Isaure Chauvot de Beauchêne
- 1] Centre national de la recherche scientifique (CNRS), unité mixte de recherche 8113, Ecole Normale Supérieure de Cachan, 61 avenue du président Wilson, 94230 Cachan, France [2] Laboratoire d'Excellence en Recherche sur le Médicament et l'Innovation Thérapeutique (LERMIT), Campus Paris Saclay, 5 rue Jean-Baptiste Clément 92296 Châtenay-Malabry, France
| | - Zakia Belaid-Choucair
- 1] Laboratoire INSERM, unité mixte de recherche 1163, centre national de la recherche scientifique (CNRS) équipe de recherche labellisée 8254, 24 Boulevard de Montparnasse, 75015 Paris, France [2] Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, Assistance publique - Hôpitaux de Paris, Hôpital Necker, 24 Boulevard de Montparnasse, 75015 Paris, France [3] Laboratory of Excellence GR-Ex, 75015 Paris, France
| | - Margaux Sevin
- 1] INSERM, unité mixte de recherche 866, Equipe labellisée Ligue contre le Cancer and Association pour la Recherche contre le Cancer, and Laboratoire d'Excellence Lipoprotéines et santé (LipSTIC), 21033 Dijon, France [2] University of Burgundy, Faculty of Medicine and Pharmacy, 7 boulevard Jeanne d'Arc, 21033 Dijon, France
| | - Thiago Trovati Maciel
- 1] Laboratoire INSERM, unité mixte de recherche 1163, centre national de la recherche scientifique (CNRS) équipe de recherche labellisée 8254, 24 Boulevard de Montparnasse, 75015 Paris, France [2] Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, Assistance publique - Hôpitaux de Paris, Hôpital Necker, 24 Boulevard de Montparnasse, 75015 Paris, France [3] Laboratory of Excellence GR-Ex, 75015 Paris, France [4] INSERM, unité mixte de recherche 699, Hôpital Bichat, 46 rue Henri Huchard, 75018 Paris, France [5] Faculté de médecine and Université Denis Diderot Paris VII, 5 Rue Thomas Mann, 75013 Paris, France
| | - Christian Auclair
- 1] Centre national de la recherche scientifique (CNRS), unité mixte de recherche 8113, Ecole Normale Supérieure de Cachan, 61 avenue du président Wilson, 94230 Cachan, France [2] Laboratoire d'Excellence en Recherche sur le Médicament et l'Innovation Thérapeutique (LERMIT), Campus Paris Saclay, 5 rue Jean-Baptiste Clément 92296 Châtenay-Malabry, France
| | - Philippe Leboulch
- 1] Commissariat à l'énergie atomique (CEA), Institute of Emerging Diseases and Innovative Therapies (iMETI), 18 Route du Panorama, 92260 Fontenay-aux-Roses, France [2] Women's Hospital and Harvard Medical School, 25 Shattuck St, Boston, Massachusetts 02115, USA
| | - Stany Chretien
- Commissariat à l'énergie atomique (CEA), Institute of Emerging Diseases and Innovative Therapies (iMETI), 18 Route du Panorama, 92260 Fontenay-aux-Roses, France
| | - Luba Tchertanov
- 1] Centre national de la recherche scientifique (CNRS), unité mixte de recherche 8113, Ecole Normale Supérieure de Cachan, 61 avenue du président Wilson, 94230 Cachan, France [2] Laboratoire d'Excellence en Recherche sur le Médicament et l'Innovation Thérapeutique (LERMIT), Campus Paris Saclay, 5 rue Jean-Baptiste Clément 92296 Châtenay-Malabry, France
| | | | - Renaud Seigneuric
- University of Burgundy, Faculty of Medicine and Pharmacy, 7 boulevard Jeanne d'Arc, 21033 Dijon, France
| | - Michaela Fontenay
- 1] Laboratory of Excellence GR-Ex, 75015 Paris, France [2] Institut Cochin, INSERM, unité mixte de recherche 1016, centre national de la recherche scientifique (CNRS), unité mixte de recherche 8104, Université Paris Descartes, and Assistance publique - Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Hôpital Cochin, Service d'hématologie biologique, 27 rue du Faubourg Saitn-Jacques, 75014 Paris, France
| | - Carmen Garrido
- 1] INSERM, unité mixte de recherche 866, Equipe labellisée Ligue contre le Cancer and Association pour la Recherche contre le Cancer, and Laboratoire d'Excellence Lipoprotéines et santé (LipSTIC), 21033 Dijon, France [2] University of Burgundy, Faculty of Medicine and Pharmacy, 7 boulevard Jeanne d'Arc, 21033 Dijon, France [3] Centre anticancéreux George François Leclerc, 1 rue professeur Marion, 21079 Dijon, France [4]
| | - Olivier Hermine
- 1] Laboratoire INSERM, unité mixte de recherche 1163, centre national de la recherche scientifique (CNRS) équipe de recherche labellisée 8254, 24 Boulevard de Montparnasse, 75015 Paris, France [2] Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, Assistance publique - Hôpitaux de Paris, Hôpital Necker, 24 Boulevard de Montparnasse, 75015 Paris, France [3] Laboratory of Excellence GR-Ex, 75015 Paris, France [4] Service d'hématologie, Faculté de médecine Paris Descartes, Sorbonne Paris-Cité et Assistance publique - Hôpitaux de Paris Hôpital Necker, 149 rue de Sèvres, 75015 Paris, France [5]
| | - Geneviève Courtois
- 1] Laboratoire INSERM, unité mixte de recherche 1163, centre national de la recherche scientifique (CNRS) équipe de recherche labellisée 8254, 24 Boulevard de Montparnasse, 75015 Paris, France [2] Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, Assistance publique - Hôpitaux de Paris, Hôpital Necker, 24 Boulevard de Montparnasse, 75015 Paris, France [3] Laboratory of Excellence GR-Ex, 75015 Paris, France [4]
| |
Collapse
|
5
|
Pereira RL, Felizardo RJF, Cenedeze MA, Hiyane MI, Bassi EJ, Amano MT, Origassa CST, Silva RC, Aguiar CF, Carneiro SM, Pesquero JB, Araújo RC, Keller ADC, Monteiro RC, Moura IC, Pacheco-Silva A, Câmara NOS. Balance between the two kinin receptors in the progression of experimental focal and segmental glomerulosclerosis in mice. Dis Model Mech 2014; 7:701-10. [PMID: 24742784 PMCID: PMC4036477 DOI: 10.1242/dmm.014548] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
Focal and segmental glomerulosclerosis (FSGS) is one of the most important renal diseases related to end-stage renal failure. Bradykinin has been implicated in the pathogenesis of renal inflammation, whereas the role of its receptor 2 (B2RBK; also known as BDKRB2) in FSGS has not been studied. FSGS was induced in wild-type and B2RBK-knockout mice by a single intravenous injection of Adriamycin (ADM). In order to further modulate the kinin receptors, the animals were also treated with the B2RBK antagonist HOE-140 and the B1RBK antagonist DALBK. Here, we show that the blockage of B2RBK with HOE-140 protects mice from the development of FSGS, including podocyte foot process effacement and the re-establishment of slit-diaphragm-related proteins. However, B2RBK-knockout mice were not protected from FSGS. These opposite results were due to B1RBK expression. B1RBK was upregulated after the injection of ADM and this upregulation was exacerbated in B2RBK-knockout animals. Furthermore, treatment with HOE-140 downregulated the B1RBK receptor. The blockage of B1RBK in B2RBK-knockout animals promoted FSGS regression, with a less-inflammatory phenotype. These results indicate a deleterious role of both kinin receptors in an FSGS model and suggest a possible cross-talk between them in the progression of disease.
Collapse
Affiliation(s)
- Rafael Luiz Pereira
- Laboratory of Clinical and Experimental Immunology, Nephrology Division, Federal University of São Paulo, São Paulo 04023-900, Brazil. Laboratory of Transplantation Immunobiology, Department of Immunology, Institute of Biomedical Sciences IV, University of São Paulo, São Paulo 05508-000, Brazil
| | - Raphael José Ferreira Felizardo
- Laboratory of Clinical and Experimental Immunology, Nephrology Division, Federal University of São Paulo, São Paulo 04023-900, Brazil
| | - Marcos Antônio Cenedeze
- Laboratory of Clinical and Experimental Immunology, Nephrology Division, Federal University of São Paulo, São Paulo 04023-900, Brazil
| | - Meire Ioshie Hiyane
- Laboratory of Transplantation Immunobiology, Department of Immunology, Institute of Biomedical Sciences IV, University of São Paulo, São Paulo 05508-000, Brazil
| | - Enio José Bassi
- Laboratory of Clinical and Experimental Immunology, Nephrology Division, Federal University of São Paulo, São Paulo 04023-900, Brazil
| | - Mariane Tami Amano
- Laboratory of Clinical and Experimental Immunology, Nephrology Division, Federal University of São Paulo, São Paulo 04023-900, Brazil
| | - Clarice Sylvia Taemi Origassa
- Laboratory of Clinical and Experimental Immunology, Nephrology Division, Federal University of São Paulo, São Paulo 04023-900, Brazil
| | - Reinaldo Correia Silva
- Laboratory of Clinical and Experimental Immunology, Translational Medicine Division, Federal University of São Paulo, São Paulo 04039-002, Brazil
| | - Cristhiane Fávero Aguiar
- Laboratory of Transplantation Immunobiology, Department of Immunology, Institute of Biomedical Sciences IV, University of São Paulo, São Paulo 05508-000, Brazil
| | - Sylvia Mendes Carneiro
- Laboratory of Cellular Biology, Instituto Butantan, Av. Vital Brazil 1500, São Paulo 05503-900, Brazil
| | - João Bosco Pesquero
- Department of Biophysics, Federal University of São Paulo (UNIFESP), São Paulo 04023-062, Brazil
| | - Ronaldo Carvalho Araújo
- Department of Biophysics, Federal University of São Paulo (UNIFESP), São Paulo 04023-062, Brazil
| | - Alexandre de Castro Keller
- Department of Microbiology, Immunology and Parasitology, Federal University of São Paulo (UNIFESP), São Paulo 04023-062, Brazil
| | - Renato C Monteiro
- Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 699, Paris 75870, France
| | - Ivan Cruz Moura
- Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 699, Paris 75870, France
| | - Alvaro Pacheco-Silva
- Laboratory of Clinical and Experimental Immunology, Nephrology Division, Federal University of São Paulo, São Paulo 04023-900, Brazil. Instituto Israelita de Ensino e Pesquisa Albert Einstein, Renal Transplantation Unit, Albert Einstein Hospital, São Paulo 05521-000, Brazil
| | - Niels Olsen Saraiva Câmara
- Laboratory of Clinical and Experimental Immunology, Nephrology Division, Federal University of São Paulo, São Paulo 04023-900, Brazil. Laboratory of Transplantation Immunobiology, Department of Immunology, Institute of Biomedical Sciences IV, University of São Paulo, São Paulo 05508-000, Brazil.
| |
Collapse
|
6
|
Lebreton C, Ménard S, Abed J, Moura IC, Coppo R, Dugave C, Monteiro RC, Fricot A, Traore MG, Griffin M, Cellier C, Malamut G, Cerf-Bensussan N, Heyman M. Interactions among secretory immunoglobulin A, CD71, and transglutaminase-2 affect permeability of intestinal epithelial cells to gliadin peptides. Gastroenterology 2012; 143:698-707.e4. [PMID: 22750506 DOI: 10.1053/j.gastro.2012.05.051] [Citation(s) in RCA: 83] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/27/2011] [Revised: 05/01/2012] [Accepted: 05/24/2012] [Indexed: 01/31/2023]
Abstract
BACKGROUND & AIMS The transferrin receptor (CD71) is up-regulated in duodenal biopsy samples from patients with active celiac disease and promotes retrotransport of secretory immunoglobulin A (SIgA)-gliadin complexes. We studied intestinal epithelial cell lines that overexpress CD71 to determine how interactions between SIgA and CD71 promote transepithelial transport of gliadin peptides. METHODS We analyzed duodenal biopsy specimens from 8 adults and 1 child with active celiac disease. Caco-2 and HT29-19A epithelial cell lines were transfected with fluorescence-labeled small interfering RNAs against CD71. Interactions among IgA, CD71, and transglutaminase 2 (Tgase2) were analyzed by flow cytometry, immunoprecipitation, and confocal microscopy. Transcytosis of SIgA-CD71 complexes and intestinal permeability to the gliadin 3H-p31-49 peptide were analyzed in polarized monolayers of Caco-2 cells. RESULTS Using fluorescence resonance energy transfer and in situ proximity ligation assays, we observed physical interactions between SIgA and CD71 or CD71 and Tgase2 at the apical surface of enterocytes in biopsy samples and monolayers of Caco-2 cells. CD71 and Tgase2 were co-precipitated with SIgA, bound to the surface of Caco-2 cells. SIgA-CD71 complexes were internalized and localized in early endosomes and recycling compartments but not in lysosomes. In the presence of celiac IgA or SIgA against p31-49, transport of intact 3H-p31-49 increased significantly across Caco-2 monolayers; this transport was inhibited by soluble CD71 or Tgase2 inhibitors. CONCLUSIONS Upon binding to apical CD71, SIgA (with or without gliadin peptides) enters a recycling pathway and avoids lysosomal degradation; this process allows apical-basal transcytosis of bound peptides. This mechanism is facilitated by Tgase2 and might be involved in the pathogenesis of celiac disease.
Collapse
Affiliation(s)
- Corinne Lebreton
- INSERM, UMR989, Paris, France; Université Paris Descartes-Sorbonne Paris Cité and Institut IMAGINE, Paris, France
| | - Sandrine Ménard
- INSERM, UMR989, Paris, France; Université Paris Descartes-Sorbonne Paris Cité and Institut IMAGINE, Paris, France
| | - Juliette Abed
- INSERM, UMR989, Paris, France; Université Paris Descartes-Sorbonne Paris Cité and Institut IMAGINE, Paris, France
| | - Ivan Cruz Moura
- INSERM, UMR699, Paris, France; Université Paris Diderot-Sorbonne Paris Cité, Paris, France
| | - Rosanna Coppo
- Medical Nephrology Unit, S. Giovanni Hospital, University of Torino, Torino, Italy
| | - Christophe Dugave
- Commissariat à Énergie Atomique, iBiTecS, Service d'Ingénierie Moléculaire des Protéines, Gif-sur-Yvette, France
| | - Renato C Monteiro
- INSERM, UMR699, Paris, France; Université Paris Diderot-Sorbonne Paris Cité, Paris, France
| | - Aurélie Fricot
- Université Paris Descartes-Sorbonne Paris Cité and Institut IMAGINE, Paris, France; CNRS, UMR8147, Hôpital Européen Georges Pompidou, Paris, France
| | - Meriem Garfa Traore
- Université Paris Descartes-Sorbonne Paris Cité and Institut IMAGINE, Paris, France; IFR 94, Imagery Platform, Hôpital Européen Georges Pompidou, Paris, France
| | - Martin Griffin
- School of Life and Health. Aston University, Birmingham B4 7ET, United Kingdom
| | - Christophe Cellier
- INSERM, UMR989, Paris, France; Université Paris Descartes-Sorbonne Paris Cité and Institut IMAGINE, Paris, France; APHP, Department of Gastroenterology, Hôpital Européen Georges Pompidou, Paris, France
| | - Georgia Malamut
- INSERM, UMR989, Paris, France; Université Paris Descartes-Sorbonne Paris Cité and Institut IMAGINE, Paris, France; APHP, Department of Gastroenterology, Hôpital Européen Georges Pompidou, Paris, France
| | - Nadine Cerf-Bensussan
- INSERM, UMR989, Paris, France; Université Paris Descartes-Sorbonne Paris Cité and Institut IMAGINE, Paris, France.
| | - Martine Heyman
- INSERM, UMR989, Paris, France; Université Paris Descartes-Sorbonne Paris Cité and Institut IMAGINE, Paris, France
| |
Collapse
|
7
|
Matysiak-Budnik T, Moura IC, Arcos-Fajardo M, Lebreton C, Ménard S, Candalh C, Ben-Khalifa K, Dugave C, Tamouza H, van Niel G, Bouhnik Y, Lamarque D, Chaussade S, Malamut G, Cellier C, Cerf-Bensussan N, Monteiro RC, Heyman M. Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. J Cell Biol 2008. [DOI: 10.1083/jcb1801oia1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
8
|
Matysiak-Budnik T, Moura IC, Arcos-Fajardo M, Lebreton C, Ménard S, Candalh C, Ben-Khalifa K, Dugave C, Tamouza H, van Niel G, Bouhnik Y, Lamarque D, Chaussade S, Malamut G, Cellier C, Cerf-Bensussan N, Monteiro RC, Heyman M. Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. ACTA ACUST UNITED AC 2007; 205:143-54. [PMID: 18166587 PMCID: PMC2234361 DOI: 10.1084/jem.20071204] [Citation(s) in RCA: 199] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Celiac disease (CD) is an enteropathy resulting from an abnormal immune response to gluten-derived peptides in genetically susceptible individuals. This immune response is initiated by intestinal transport of intact peptide 31-49 (p31-49) and 33-mer gliadin peptides through an unknown mechanism. We show that the transferrin receptor CD71 is responsible for apical to basal retrotranscytosis of gliadin peptides, a process during which p31-49 and 33-mer peptides are protected from degradation. In patients with active CD, CD71 is overexpressed in the intestinal epithelium and colocalizes with immunoglobulin (Ig) A. Intestinal transport of intact p31-49 and 33-mer peptides was blocked by polymeric and secretory IgA (SIgA) and by soluble CD71 receptors, pointing to a role of SIgA–gliadin complexes in this abnormal intestinal transport. This retrotranscytosis of SIgA–gliadin complexes may promote the entry of harmful gliadin peptides into the intestinal mucosa, thereby triggering an immune response and perpetuating intestinal inflammation. Our findings strongly implicate CD71 in the pathogenesis of CD.
Collapse
Affiliation(s)
- Tamara Matysiak-Budnik
- Institut National de la Santé et de la Recherche Médicale (INSERM), U793, Paris 75730, Cedex 15, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Callens C, Moura IC, Lepelletier Y, Coulon S, Renand A, Dussiot M, Ghez D, Benhamou M, Monteiro RC, Bazarbachi A, Hermine O. Recent advances in adult T-cell leukemia therapy: focus on a new anti-transferrin receptor monoclonal antibody. Leukemia 2007; 22:42-8. [PMID: 17898788 DOI: 10.1038/sj.leu.2404958] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
HTLV-I is an endemic retrovirus responsible for the adult T-cell leukemia/lymphoma (ATLL). This aggressive lymphoid proliferation is associated with a bad prognosis due to the resistance of HTLV-I-infected cells to most classical chemotherapeutic agents. Here we review recent advances in ATLL immunotherapy. We particularly focus on promising data from our group, characterizing a new mouse monoclonal antibody (mAb A24) against the human transferrin receptor (TfR-1). Monoclonal antibodies to target cell differentiation markers on ATLL cells have already been proposed as therapeutic agents. However, in clinical trials acute forms of ATLL were resistant to these immunotherapies. A24 binds TfR-1 (K(d) 2.7 nM) and competes with transferrin for receptor binding. It blocks the proliferation of malignant cells (TfR-1(high)), such as HTLV-I-infected T cells but not of resting cells. A24 induces TfR-1 endocytosis in lysosomal compartments where the receptor is degraded leading to intracellular iron deprivation. In HTLV-I-infected cells, A24 targets and induces apoptosis of both chronic and acute ATLL forms, independent of antibody aggregation, antibody-dependent cellular cytotoxicity and/or complement addition. The antibody efficacy was confirmed in animal models. We are currently developing strategies to use A24 in clinical trials.
Collapse
Affiliation(s)
- C Callens
- CNRS UMR 8147, Université Paris 5, Faculté de Médecine Necker, Paris, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Kantari C, Pederzoli-Ribeil M, Amir-Moazami O, Gausson-Dorey V, Moura IC, Lecomte MC, Benhamou M, Witko-Sarsat V. Proteinase 3, the Wegener autoantigen, is externalized during neutrophil apoptosis: evidence for a functional association with phospholipid scramblase 1 and interference with macrophage phagocytosis. Blood 2007; 110:4086-95. [PMID: 17712045 DOI: 10.1182/blood-2007-03-080457] [Citation(s) in RCA: 87] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
Proteinase 3 (PR3), a serine proteinase contained in neutrophil azurophilic granules, is considered a risk factor for vasculitides and rheumatoid arthritis when expressed on the outer leaflet of neutrophil plasma membrane and is the preferred target of antineutrophil cytoplasm autoantibodies (ANCA) in Wegener granulomatosis. ANCA binding to PR3 expressed at the surface of neutrophils activates them. Evidence is provided that neutrophil apoptosis induced significantly more membrane PR3 expression without degranulation (but no enhanced membrane CD35, CD66b, CD63, myeloperoxidase, or elastase expression). This observation was confirmed on cytoplasts, a model of granule-free neutrophils. We hypothesized that PR3 could interact with proteins involved in membrane flip-flop (eg, phospholipid scramblase 1 [PLSCR1]). PR3-PLSCR1 interaction in neutrophils was demonstrated by confocal microscopy and coimmunoprecipitation. In the RBL-2H3 rat mast-cell line stably transfected with PR3 or its inactive mutant (PR3S203A), PR3 externalization depended on PLSCR1, as shown by less PR3 externalization in the presence of rPLSCR1 siRNA, but independently of its serine-proteinase activity. Finally, apoptosis-externalized PR3 decreased the human macrophage-phagocytosis rate of apoptotic PR3 transfectants. Therefore, in addition to ANCA binding in vasculitis, the proinflammatory role of membrane PR3 expression may involve interference with macrophage clearance of apoptotic neutrophils.
Collapse
MESH Headings
- Animals
- Antibodies, Antineutrophil Cytoplasmic/immunology
- Antibodies, Antineutrophil Cytoplasmic/metabolism
- Antigens, CD/genetics
- Antigens, CD/immunology
- Antigens, CD/metabolism
- Apoptosis/genetics
- Apoptosis/immunology
- Arthritis, Rheumatoid/enzymology
- Arthritis, Rheumatoid/genetics
- Arthritis, Rheumatoid/immunology
- Cell Line
- Cell Membrane/enzymology
- Cell Membrane/genetics
- Cell Membrane/immunology
- Gene Expression Regulation, Enzymologic/immunology
- Granulomatosis with Polyangiitis/enzymology
- Granulomatosis with Polyangiitis/genetics
- Granulomatosis with Polyangiitis/immunology
- Humans
- Macrophages/enzymology
- Macrophages/immunology
- Mast Cells/enzymology
- Mast Cells/immunology
- Mutation/immunology
- Myeloblastin/genetics
- Myeloblastin/immunology
- Myeloblastin/metabolism
- Neutrophil Activation/genetics
- Neutrophil Activation/immunology
- Neutrophils/enzymology
- Neutrophils/immunology
- Neutrophils/metabolism
- Pancreatic Elastase/genetics
- Pancreatic Elastase/immunology
- Pancreatic Elastase/metabolism
- Peroxidase/genetics
- Peroxidase/immunology
- Peroxidase/metabolism
- Phagocytosis/genetics
- Phagocytosis/immunology
- Phospholipid Transfer Proteins/genetics
- Phospholipid Transfer Proteins/immunology
- Phospholipid Transfer Proteins/metabolism
- Protein Transport/genetics
- Protein Transport/immunology
- RNA, Small Interfering/genetics
- RNA, Small Interfering/immunology
- Rats
- Risk Factors
- Secretory Vesicles/enzymology
- Secretory Vesicles/genetics
- Secretory Vesicles/immunology
- Vasculitis/enzymology
- Vasculitis/genetics
- Vasculitis/immunology
Collapse
Affiliation(s)
- Chahrazade Kantari
- Institut National de la Santé et de la Recherche Médicale, U845, Paris, France
| | | | | | | | | | | | | | | |
Collapse
|
11
|
Coulon S, Vandekerckhove J, Dussiot M, Callens C, Suarez F, Kersual J, Asnafi V, Belaid Z, Courtois G, Giraudier S, Dubreuil P, Lepelletier Y, Moura IC, Hermine O. Human erythroleukemia: is the two-hit model of mouse leukemogenesis valid in human disease? Leukemia 2007; 21:2212-4. [PMID: 17541393 DOI: 10.1038/sj.leu.2404779] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
12
|
Ribeil JA, Zermati Y, Vandekerckhove J, Cathelin S, Kersual J, Dussiot M, Coulon S, Moura IC, Zeuner A, Kirkegaard-Sørensen T, Varet B, Solary E, Garrido C, Hermine O. Hsp70 regulates erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1. Nature 2006; 445:102-5. [PMID: 17167422 DOI: 10.1038/nature05378] [Citation(s) in RCA: 201] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2006] [Accepted: 10/25/2006] [Indexed: 01/22/2023]
Abstract
Caspase-3 is activated during both terminal differentiation and erythropoietin-starvation-induced apoptosis of human erythroid precursors. The transcription factor GATA-1, which performs an essential function in erythroid differentiation by positively regulating promoters of erythroid and anti-apoptotic genes, is cleaved by caspases in erythroid precursors undergoing cell death upon erythropoietin starvation or engagement of the death receptor Fas. In contrast, by an unknown mechanism, GATA-1 remains uncleaved when these cells undergo terminal differentiation upon stimulation with Epo. Here we show that during differentiation, but not during apoptosis, the chaperone protein Hsp70 protects GATA-1 from caspase-mediated proteolysis. At the onset of caspase activation, Hsp70 co-localizes and interacts with GATA-1 in the nucleus of erythroid precursors undergoing terminal differentiation. In contrast, erythropoietin starvation induces the nuclear export of Hsp70 and the cleavage of GATA-1. In an in vitro assay, Hsp70 protects GATA-1 from caspase-3-mediated proteolysis through its peptide-binding domain. The use of RNA-mediated interference to decrease the Hsp70 content of erythroid precursors cultured in the presence of erythropoietin leads to GATA-1 cleavage, a decrease in haemoglobin content, downregulation of the expression of the anti-apoptotic protein Bcl-X(L), and cell death by apoptosis. These effects are abrogated by the transduction of a caspase-resistant GATA-1 mutant. Thus, in erythroid precursors undergoing terminal differentiation, Hsp70 prevents active caspase-3 from cleaving GATA-1 and inducing apoptosis.
Collapse
Affiliation(s)
- Jean-Antoine Ribeil
- CNRS UMR 8147, Faculté de Médecine et Université René Descartes Paris V, Institut Fédérative Necker, 75270 Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Lepelletier Y, Moura IC, Hadj-Slimane R, Renand A, Fiorentino S, Baude C, Shirvan A, Barzilai A, Hermine O. Immunosuppressive role of semaphorin-3A on T cell proliferation is mediated by inhibition of actin cytoskeleton reorganization. Eur J Immunol 2006; 36:1782-93. [PMID: 16791896 DOI: 10.1002/eji.200535601] [Citation(s) in RCA: 138] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Timely negative regulation of the immune system is critical to allow it to perform its duty while maintaining it under tight control to avoid overactivation. We previously reported that the neuronal receptor neuropilin-1 (NP-1) is expressed in human lymph nodes. However, the role of NP-1 interaction with its physiological ligand semaphorin-3A (Sema-3A) on immune cells remains elusive. Here we show that Sema-3A is expressed by activated DC and T cells, and that its secretion in DC/T cell cocultures is delayed. Sema-3A/NP-1 interaction down-modulated T cell activation since addition of Sema-3A in DC/T cell cocultures dramatically inhibited allogeneic T cell proliferation. More importantly, neutralization by blocking antibodies or by antagonist peptide of endogenous Sema-3A produced by DC/T cell cocultures resulted in a 130% increase in T cell proliferation. Sema-3A acted directly on T cells, since it could block anti-CD3/CD28-stimulated proliferation of T cells. Finally, immunomodulatory functions of Sema-3A relied on the blockage of actin cytoskeleton reorganization, affecting TCR polarization and interfering with early TCR signal transduction events such as ZAP-70 or focal adhesion kinase phosphorylation. Therefore, we propose that Sema-3A secretion and the resulting NP-1/Sema-3A interaction are involved in a late negative feedback loop controlling DC-induced T cell proliferation.
Collapse
Affiliation(s)
- Yves Lepelletier
- CNRS UMR 8147, Faculté de médecine, Université René Descartes, Paris V, Hôpital Necker, Assistance Publique-Hôpitaux de Paris, Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Savina A, Jancic C, Hugues S, Guermonprez P, Vargas P, Moura IC, Lennon-Duménil AM, Seabra MC, Raposo G, Amigorena S. NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell 2006; 126:205-18. [PMID: 16839887 DOI: 10.1016/j.cell.2006.05.035] [Citation(s) in RCA: 653] [Impact Index Per Article: 36.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2005] [Revised: 03/10/2006] [Accepted: 05/03/2006] [Indexed: 12/29/2022]
Abstract
To initiate adaptative cytotoxic immune responses, proteolytic peptides derived from phagocytosed antigens are presented by dendritic cells (DCs) to CD8+ T lymphocytes through a process called antigen "crosspresentation." The partial degradation of antigens mediated by lysosomal proteases in an acidic environment must be tightly controlled to prevent destruction of potential peptides for T cell recognition. We now describe a specialization of the phagocytic pathway of DCs that allows a fine control of antigen processing. The NADPH oxidase NOX2 is recruited to the DC's early phagosomes and mediates the sustained production of low levels of reactive oxygen species, causing active and maintained alkalinization of the phagosomal lumen. DCs lacking NOX2 show enhanced phagosomal acidification and increased antigen degradation, resulting in impaired crosspresentation. Therefore, NOX2 plays a critical role in conferring DCs the ability to function as specialized phagocytes adapted to process antigens rather than kill pathogens.
Collapse
Affiliation(s)
- Ariel Savina
- Institut Curie, INSERM U653, Immunité et Cancer, 26 rue d'Ulm, 75248 Paris, Cedex 05, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Treiner E, Duban L, Moura IC, Hansen T, Gilfillan S, Lantz O. Mucosal-associated invariant T (MAIT) cells: an evolutionarily conserved T cell subset. Microbes Infect 2005; 7:552-9. [PMID: 15777741 DOI: 10.1016/j.micinf.2004.12.013] [Citation(s) in RCA: 93] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2004] [Accepted: 12/14/2004] [Indexed: 01/10/2023]
Abstract
Besides mainstream TCRalphabeta T cells harboring a very diverse repertoire, two subsets display an evolutionarily conserved invariant repertoire. This striking conservation indicates important and unique functions. CD1d-restricted NK-T cells expressing an invariant Valpha14 TCRalpha chain have been implicated in microbial and tumor responses as well as in auto-immunity. In this review, we describe the other subset, which bears the canonical hValpha7.2/mValpha19-Jalpha33 TCRalpha chain paired with a restricted set of Vbeta segments. These invariant T cells are present in mice, humans and cattle. They are preferentially located in the gut lamina propria (LP) of humans and mice and are therefore called mucosal-associated invariant T (MAIT) cells. Selection/expansion of this population requires B lymphocytes expressing MR1, a monomorphic major histocompatibility complex class I-related molecule that is also strikingly conserved in diverse mammalian species. MAIT cells are not present in germ-free mice, indicating that commensal flora is required for their expansion in the gut LP. The nature of the ligand and the putative functions of these MAIT cells are discussed.
Collapse
Affiliation(s)
- Emmanuel Treiner
- Laboratoire d'Immunologie and Inserm U520, Institut Curie, 26, rue d'Ulm, 70005 Paris, France
| | | | | | | | | | | |
Collapse
|
16
|
Monteiro RC, Leroy V, Launay P, Moura IC, Arcos-Fajardo M, Benhamou M, Haddad E. Pathogénie de la maladie de Berger : implication des immunoglobulines A et de leurs récepteurs. Med Sci (Paris) 2003; 19:1233-41. [PMID: 14691748 DOI: 10.1051/medsci/200319121233] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Immunoglobulin A (IgA) nephropathy or Berger's disease is the most common form of primary glomerulonephritis in the world and one of the first cause of end-stage renal failure. IgA nephropathy is characterized by the accumulation in mesangial areas of immune complexes containing polymeric IgA1. While epidemiology and clinical studies of IgA nephropathy are well established, the mechanism(s) underlying disease development is poorly understood. The pathogenesis of this disease involves the deposition of polymeric and undergalactosylated IgA1 in the mesangium. Quantitative and structural changes of IgA1 play a key role in the development of the disease due to functional abnormalities of two IgA receptors: The FcalphaR (CD89) expressed by blood myeloid cells and the transferrin receptor (CD71) on mesangial cells. Abnormal IgA induce the release of soluble CD89 which is responsible for the formation of circulating IgA complexes. These complexes may be trapped by CD71 that is overexpressed on mesangial cells in IgA nephropathy patients allowing pathogenic IgA complex formation.
Collapse
Affiliation(s)
- Renato C Monteiro
- Inserm EMI-U 0225, UFR de Médecine Xavier Bichat, 16, rue Henri-Huchard, 75018 Paris, France.
| | | | | | | | | | | | | |
Collapse
|
17
|
Moura IC, Wunderlich G, Uhrig ML, Couto AS, Peres VJ, Katzin AM, Kimura EA. Limonene arrests parasite development and inhibits isoprenylation of proteins in Plasmodium falciparum. Antimicrob Agents Chemother 2001; 45:2553-8. [PMID: 11502528 PMCID: PMC90691 DOI: 10.1128/aac.45.9.2553-2558.2001] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2000] [Accepted: 06/18/2001] [Indexed: 11/20/2022] Open
Abstract
Isoprenylation is an essential protein modification in eukaryotic cells. Herein, we report that in Plasmodium falciparum, a number of proteins were labeled upon incubation of intraerythrocytic forms with either [(3)H]farnesyl pyrophosphate or [(3)H]geranylgeranyl pyrophosphate. By thin-layer chromatography, we showed that attached isoprenoids are partially modified to dolichol and other, uncharacterized, residues, confirming active isoprenoid metabolism in this parasite. Incubation of blood-stage P. falciparum treated with the isoprenylation inhibitor limonene significantly decreased the parasites' progression from the ring stage to the trophozoite stage and at 1.22 mM, 50% of the parasites died after the first cycle. Using Ras- and Rap-specific monoclonal antibodies, putative Rap and Ras proteins of P. falciparum were immunoprecipitated. Upon treatment with 0.5 mM limonene, isoprenylation of these proteins was significantly decreased, possibly explaining the observed arrest of parasite development.
Collapse
Affiliation(s)
- I C Moura
- Departamento de Parasitologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil
| | | | | | | | | | | | | |
Collapse
|
18
|
Wunderlich G, Moura IC, del Portillo HA. Genetic immunization of BALB/c mice with a plasmid bearing the gene coding for a hybrid merozoite surface protein 1-hepatitis B virus surface protein fusion protects mice against lethal Plasmodium chabaudi chabaudi PC1 infection. Infect Immun 2000; 68:5839-45. [PMID: 10992493 PMCID: PMC101545 DOI: 10.1128/iai.68.10.5839-5845.2000] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The genetic immunization of rodents with a plasmid coding for a Plasmodium chabaudi merozoite surface protein 1 (C terminus)-hepatitis B virus surface fusion protein (pPcMSP1(19)-HBs) provided protection of mice against subsequent lethal challenge with P. chabaudi chabaudi PC1-infected red blood cells. The percentage of survivor mice was higher in DNA-immunized mice than in animals immunized with a recombinant rPcMSP1(19)- glutathione S-transferase fusion protein administered in Freund adjuvant. In all mice immunized with the pPcMSP1(19)-HBs, a Th1-specific response, including the production of anti-MSP1(19)-specific immunoglobulins predominantly of the immunoglobulin G2a subtype and reacting almost exclusively against discontinuous epitopes, was elicited. The coinjection of Th1-type cytokine-expressing plasmids (gamma interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor) mostly abolished protection and boosting of MSP1(19)-specific antibodies. The inclusion of a lymph node-targeting signal did not significantly increase protection. These data provide further evidence that MSP1(19)-HBs DNA constructs might be useful as components of a genetic vaccine against the asexual blood stages of Plasmodium.
Collapse
Affiliation(s)
- G Wunderlich
- Instituto Ciências Biomédicas 2, Universidade de São Paulo, São Paulo SP, CEP 05508-900, Brazil.
| | | | | |
Collapse
|
19
|
Moura IC, Pudles J. A Plasmodium chabaudi chabaudi high molecular mass glycoprotein translocated to the host cell membrane by a non-classical secretory pathway. Eur J Cell Biol 1999; 78:186-93. [PMID: 10219568 DOI: 10.1016/s0171-9335(99)80097-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
We have purified and characterized a novel high molecular mass glycoprotein of P. chabaudi chabaudi (Pc550gp) that is transported to the erythrocyte membrane during the intraerythrocytic cycle. Immuno fluorescence assays with polyclonal monospecific antibodies against Pc550gp show that the protein to be localized in the periphery of young trophozoite stages i.e., on the plasma membrane or parasitophorous vacuole membrane. However, in late trophozoites and schizonts the antigen is distributed in both parasite and host cell membranes. These results were confirmed by immunoblotting of isolated parasites and infected host cell membranes at different stages of parasite development. Moreover, alkali extraction of purified infected erythrocyte membranes at mature stages of parasite development does not solubilize Pc550gp, suggesting that it is an integral membrane protein. In addition proteinase K digestion of intact infected host cells induced the disappearance of Pc550gp. Further indicating its transmembrane nature and that it presents extracellular domains susceptible to proteolysis. Brefeldin A or low temperature (15 degrees C) treatment did not affect the translocation of Pc550gp from the parasite compartments to the erythrocyte membrane, indicating that the secretion of Pc550gp does not follow the classical transport pathway described in most eukaryotic cells.
Collapse
Affiliation(s)
- I C Moura
- Departamento de Parasitologia, Universidade de São Paulo, Brazil.
| | | |
Collapse
|
20
|
Furtado GC, Moura IC, Pudles J, Alvarez JM, D'Império Lima MR. Plasmodium chabaudi chabaudi: a monoclonal antibody raised against soluble antigens present in the plasma of infected mice recognizes a 250-kDa schizont glycoprotein that is secreted during schizogony. Exp Parasitol 1999; 91:97-100. [PMID: 9920048 DOI: 10.1006/expr.1999.4329] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- G C Furtado
- Departamento de Imunologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, SP, Brasil
| | | | | | | | | |
Collapse
|